A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma

M. L. Cloud, G. C. Enas, J. Kemp, T. Platts-Mills, L. C. Altman, R. Townley, D. Tinkelman, T. King, E. Middleton, A. L. Sheffer, E. R. McFadden, D. S. Farlow

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

LY171883 is a new selective LTD4/LTE4-receptor antagonist. To evaluate the efficacy of LY 171883, we studied 138 nonsmoking asthmatic patients, 18 to 65 yr old, in a double-blind, randomized block-design study. All patients were required to demonstrate a ≥15% increase in FEV1 after inhaled bronchodilator use and were then randomnly assigned to either LY171883 (600 mg) or placebo twice daily for 6 weeks. Assessment of efficacy was measured by inhaled metaproterenol use (mg/wk), symptoms, twice-daily peak expiratory flow, and weekly FEV1 measurements. LY171883-treated patients had improved FEV1 values upon completion of the treatment period compared with placebo recipients (p = 0.003). Metaproterenol use decreased in both groups, but treatment differences, though not statistically significant, favored LY171883 (p = 0.089). Of patients who used at least 23 mg/wk of metaproterenol (36 inhalations) at initiation of the study, those who received LY171883 used significantly less metaproterenol than those who received placebo (p = 0.007). LY171883 was well tolerated and reduced the need for a bronchodilator drug while improving pulmonary function. Results of this study support the hypothesis that leukotrienes LTD4 and/or LTE4 may be important in the pathogenesis of asthma in humans.

Original languageEnglish
Pages (from-to)1336-1339
Number of pages4
JournalAmerican Review of Respiratory Disease
Volume140
Issue number5
StatePublished - 1989
Externally publishedYes

Fingerprint

LY 171883
Metaproterenol
Asthma
Lung
Bronchodilator Agents
Placebos
Leukotriene E4
Leukotriene D4
Leukotrienes
leukotriene D4 receptor
leukotriene E4 receptor
Inhalation

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Cloud, M. L., Enas, G. C., Kemp, J., Platts-Mills, T., Altman, L. C., Townley, R., ... Farlow, D. S. (1989). A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. American Review of Respiratory Disease, 140(5), 1336-1339.

A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. / Cloud, M. L.; Enas, G. C.; Kemp, J.; Platts-Mills, T.; Altman, L. C.; Townley, R.; Tinkelman, D.; King, T.; Middleton, E.; Sheffer, A. L.; McFadden, E. R.; Farlow, D. S.

In: American Review of Respiratory Disease, Vol. 140, No. 5, 1989, p. 1336-1339.

Research output: Contribution to journalArticle

Cloud, ML, Enas, GC, Kemp, J, Platts-Mills, T, Altman, LC, Townley, R, Tinkelman, D, King, T, Middleton, E, Sheffer, AL, McFadden, ER & Farlow, DS 1989, 'A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma', American Review of Respiratory Disease, vol. 140, no. 5, pp. 1336-1339.
Cloud ML, Enas GC, Kemp J, Platts-Mills T, Altman LC, Townley R et al. A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. American Review of Respiratory Disease. 1989;140(5):1336-1339.
Cloud, M. L. ; Enas, G. C. ; Kemp, J. ; Platts-Mills, T. ; Altman, L. C. ; Townley, R. ; Tinkelman, D. ; King, T. ; Middleton, E. ; Sheffer, A. L. ; McFadden, E. R. ; Farlow, D. S. / A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. In: American Review of Respiratory Disease. 1989 ; Vol. 140, No. 5. pp. 1336-1339.
@article{197fc6551d1f49e3927587ee216744e9,
title = "A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma",
abstract = "LY171883 is a new selective LTD4/LTE4-receptor antagonist. To evaluate the efficacy of LY 171883, we studied 138 nonsmoking asthmatic patients, 18 to 65 yr old, in a double-blind, randomized block-design study. All patients were required to demonstrate a ≥15{\%} increase in FEV1 after inhaled bronchodilator use and were then randomnly assigned to either LY171883 (600 mg) or placebo twice daily for 6 weeks. Assessment of efficacy was measured by inhaled metaproterenol use (mg/wk), symptoms, twice-daily peak expiratory flow, and weekly FEV1 measurements. LY171883-treated patients had improved FEV1 values upon completion of the treatment period compared with placebo recipients (p = 0.003). Metaproterenol use decreased in both groups, but treatment differences, though not statistically significant, favored LY171883 (p = 0.089). Of patients who used at least 23 mg/wk of metaproterenol (36 inhalations) at initiation of the study, those who received LY171883 used significantly less metaproterenol than those who received placebo (p = 0.007). LY171883 was well tolerated and reduced the need for a bronchodilator drug while improving pulmonary function. Results of this study support the hypothesis that leukotrienes LTD4 and/or LTE4 may be important in the pathogenesis of asthma in humans.",
author = "Cloud, {M. L.} and Enas, {G. C.} and J. Kemp and T. Platts-Mills and Altman, {L. C.} and R. Townley and D. Tinkelman and T. King and E. Middleton and Sheffer, {A. L.} and McFadden, {E. R.} and Farlow, {D. S.}",
year = "1989",
language = "English",
volume = "140",
pages = "1336--1339",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "5",

}

TY - JOUR

T1 - A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma

AU - Cloud, M. L.

AU - Enas, G. C.

AU - Kemp, J.

AU - Platts-Mills, T.

AU - Altman, L. C.

AU - Townley, R.

AU - Tinkelman, D.

AU - King, T.

AU - Middleton, E.

AU - Sheffer, A. L.

AU - McFadden, E. R.

AU - Farlow, D. S.

PY - 1989

Y1 - 1989

N2 - LY171883 is a new selective LTD4/LTE4-receptor antagonist. To evaluate the efficacy of LY 171883, we studied 138 nonsmoking asthmatic patients, 18 to 65 yr old, in a double-blind, randomized block-design study. All patients were required to demonstrate a ≥15% increase in FEV1 after inhaled bronchodilator use and were then randomnly assigned to either LY171883 (600 mg) or placebo twice daily for 6 weeks. Assessment of efficacy was measured by inhaled metaproterenol use (mg/wk), symptoms, twice-daily peak expiratory flow, and weekly FEV1 measurements. LY171883-treated patients had improved FEV1 values upon completion of the treatment period compared with placebo recipients (p = 0.003). Metaproterenol use decreased in both groups, but treatment differences, though not statistically significant, favored LY171883 (p = 0.089). Of patients who used at least 23 mg/wk of metaproterenol (36 inhalations) at initiation of the study, those who received LY171883 used significantly less metaproterenol than those who received placebo (p = 0.007). LY171883 was well tolerated and reduced the need for a bronchodilator drug while improving pulmonary function. Results of this study support the hypothesis that leukotrienes LTD4 and/or LTE4 may be important in the pathogenesis of asthma in humans.

AB - LY171883 is a new selective LTD4/LTE4-receptor antagonist. To evaluate the efficacy of LY 171883, we studied 138 nonsmoking asthmatic patients, 18 to 65 yr old, in a double-blind, randomized block-design study. All patients were required to demonstrate a ≥15% increase in FEV1 after inhaled bronchodilator use and were then randomnly assigned to either LY171883 (600 mg) or placebo twice daily for 6 weeks. Assessment of efficacy was measured by inhaled metaproterenol use (mg/wk), symptoms, twice-daily peak expiratory flow, and weekly FEV1 measurements. LY171883-treated patients had improved FEV1 values upon completion of the treatment period compared with placebo recipients (p = 0.003). Metaproterenol use decreased in both groups, but treatment differences, though not statistically significant, favored LY171883 (p = 0.089). Of patients who used at least 23 mg/wk of metaproterenol (36 inhalations) at initiation of the study, those who received LY171883 used significantly less metaproterenol than those who received placebo (p = 0.007). LY171883 was well tolerated and reduced the need for a bronchodilator drug while improving pulmonary function. Results of this study support the hypothesis that leukotrienes LTD4 and/or LTE4 may be important in the pathogenesis of asthma in humans.

UR - http://www.scopus.com/inward/record.url?scp=0024474179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024474179&partnerID=8YFLogxK

M3 - Article

VL - 140

SP - 1336

EP - 1339

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 5

ER -